Glofitamab: all 63 studies that test it
Page 1 of 1. Open to participants first (39), then studies with results posted, then the rest; newest registration first within each.
- Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System LymphomaNot yet recruitingNCT07888621Phase 2
- Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell LymphomaNot yet recruitingNCT07774234Phase 2
- Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCLRecruitingNCT07749365Phase 2
- Glofitamab in B-NHL Using Mid-Therapy Intratumoral TranscriptomicsNot yet recruitingNCT07748364Phase 2
- Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit LymphomaNot yet recruitingNCT07724457Phase 2/3
- AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCLNot yet recruitingNCT07717177Phase 2
- GLORY: Glofit-GemOx With Liso-Cel For LymphomaRecruitingNCT07711483Phase 2
- A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOPNot yet recruitingNCT07702851Phase 2
- AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")Not yet recruitingNCT07649304Phase 1
- Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell LymphomaNot yet recruitingNCT07634289Phase 2
- A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaNot yet recruitingNCT07599423Phase 2
- AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCLNot yet recruitingNCT07594899Phase 2
- External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCLRecruitingNCT07528352Phase 1
- TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell LymphomaNot yet recruitingNCT07502872Phase 2
- Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT07460362Phase 2
- Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell TherapyRecruitingNCT07453095Phase 2
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell LymphomaNot yet recruitingNCT07444710Phase 1
- Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell LymphomasNot yet recruitingNCT07387848Phase 2
- Glofitamab Combined With CAR-T Therapy in R/R DLBCLNot yet recruitingNCT07326371Phase 2
- Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 StudyRecruitingNCT07257055Phase 2
- The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical StudyRecruitingNCT07240194Phase 2
- Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell LymphomaNot yet recruitingNCT07231250Phase 2
- Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCLRecruitingNCT07012980Phase 2
- Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell TherapyRecruitingNCT07003295Phase 2
- Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor BurdenRecruitingNCT06867536Phase 2
- A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell LymphomaRecruitingNCT06765317Phase 2
- A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell LymphomaNot yet recruitingNCT06656221Phase 2
- Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCLRecruitingNCT06570447Phase 2
- CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic FactorsNot yet recruitingNCT06567366Phase 2
- Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL TrialRecruitingNCT06357676Phase 1/2
- Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT06252675Phase 2
- A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell LymphomaRecruitingNCT06213311Phase 2
- Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter SyndromeRecruitingNCT06186648Phase 2
- A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaRecruitingNCT06084936Phase 3
- A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell LymphomaRecruitingNCT06071871Phase 2
- Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT06054776Phase 2
- Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)RecruitingNCT06050694Phase 2
- A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.RecruitingNCT05833763Phase 2
- A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell LymphomaRecruitingNCT05800366Phase 2
- A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell LymphomaActive, not recruitingNCT04980222Phase 2Results posted
- A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell LymphomaCompletedNCT04313608Phase 1Results posted
- Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT07480850Phase 2
- Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System LymphomaSuspendedNCT06922604Phase 1
- A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell LymphomaWithdrawnNCT06670105Phase 2
- A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT06624085Phase 1
- Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell TherapyActive, not recruitingNCT06552572Phase 2
- A Study of Glofitamab and Lenalidomide in People With Mantle Cell LymphomaActive, not recruitingNCT06192888Phase 1
- An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell LymphomaActive, not recruitingNCT06047080Phase 3
- A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.TerminatedNCT05896163Phase 1/2
- Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell LymphomaSuspendedNCT05861050Phase 1/2
- Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOPActive, not recruitingNCT05798156Phase 2
- Glofit and Obin in Follicular Lymphoma and Marginal Zone LymphomaActive, not recruitingNCT05783596Phase 2
- A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell LymphomaCompletedNCT05364424Phase 1
- GPL in Patients with Relapsed/refractory Diffuse Large B Cell LymphomaActive, not recruitingNCT05335018Phase 2
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT05169515Phase 1
- CAR-T Followed by Bispecific AntibodiesActive, not recruitingNCT04889716Phase 2
- Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells TherapyCompletedNCT04703686Phase 2
- A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT04657302Phase 1
- A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT04408638Phase 3
- Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell LymphomaActive, not recruitingNCT04231877Phase 1/2
- Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell LymphomaActive, not recruitingNCT04161248Early Phase 1
- A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaActive, not recruitingNCT04077723Phase 1/2
- A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's LymphomaActive, not recruitingNCT03075696Phase 1/2